Holders — by stockHoldings — by fund
BAKER BROS. ADVISORS LP
Everything this manager disclosed owning in US-listed stocks — its complete Form 13F portfolio · as of 2026-06-30 · filed with the SEC up to 45 days after quarter end · CIK 0001263508
$19.96B
disclosed book value
84
positions
17.5%
largest position share
Positions, as of 2026-06-30
top 84 of 84 · 13F covers long US-listed positions only — cash, bonds, private and foreign stakes are not disclosed · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | 30.8M | $3.49B | 17.5% |
| 2 | ONCBeOne Medicines Ltd. | 8.8M | $2.51B | 12.6% |
| 3 | RVMDRevolution Medicines, Inc. | 11.4M | $2.14B | 10.7% |
| 4 | MDGLMadrigal Pharmaceuticals, Inc. | 2.1M | $1.15B | 5.8% |
| 5 | ACADACADIA Pharmaceuticals Inc. | 42.9M | $1.09B | 5.4% |
| 6 | KYMRKymera Therapeutics, Inc. | 8.7M | $992.7M | 5% |
| 7 | INSMInsmed Incorporated | 8.8M | $937.8M | 4.7% |
| 8 | CELCCelcuity Inc. | 7.9M | $828.2M | 4.2% |
| 9 | KODKodiak Sciences Inc. | 19.9M | $776.1M | 3.9% |
| 10 | RYTMRhythm Pharmaceuticals, Inc. | 5.6M | $622.3M | 3.1% |
| 11 | PRAXPraxis Precision Medicines, Inc. | 1.8M | $587.0M | 2.9% |
| 12 | ALKSAlkermes plc | 10.0M | $524.6M | 2.6% |
| 13 | SMMTSummit Therapeutics Inc. | 32.8M | $477.7M | 2.4% |
| 14 | GRALGRAIL, Inc. | 4.0M | $275.0M | 1.4% |
| 15 | ABCLAbCellera Biologics Inc. | 33.0M | $259.1M | 1.3% |
| 16 | IMVTImmunovant, Inc. | 5.4M | $209.4M | 1% |
| 17 | IDYAIDEAYA Biosciences, Inc. | 5.0M | $186.7M | 0.9% |
| 18 | KNSAKiniksa Pharmaceuticals International, plc | 2.8M | $181.3M | 0.9% |
| 19 | ROIVRoivant Sciences Ltd. | 4.7M | $166.9M | 0.8% |
| 20 | ARWRArrowhead Pharmaceuticals, Inc. | 2.0M | $162.4M | 0.8% |
| 21 | IONSIonis Pharmaceuticals, Inc. | 2.0M | $162.4M | 0.8% |
| 22 | EWTXEdgewise Therapeutics, Inc. | 3.7M | $150.4M | 0.8% |
| 23 | REPLReplimune Group, Inc. | 11.0M | $122.3M | 0.6% |
| 24 | NRIXNurix Therapeutics, Inc. | 4.7M | $113.0M | 0.6% |
| 25 | STOKStoke Therapeutics, Inc. | 3.3M | $109.2M | 0.5% |
| 26 | GLUEMonte Rosa Therapeutics, Inc. | 4.3M | $105.2M | 0.5% |
| 27 | IMTXImmatics N.V. | 9.5M | $96.3M | 0.5% |
| 28 | DNLIDenali Therapeutics Inc. | 3.7M | $96.0M | 0.5% |
| 29 | CRNXCrinetics Pharmaceuticals, Inc. | 2.4M | $88.0M | 0.4% |
| 30 | DNTHDianthus Therapeutics, Inc. | 852,164 | $83.1M | 0.4% |
| 31 | GPCRStructure Therapeutics Inc. | 1.4M | $76.9M | 0.4% |
| 32 | CELC 2.75 08/01/31Celcuity Inc. | 30.8M | $69.2M | 0.3% |
| 33 | RAPPRapport Therapeutics, Inc. | 1.5M | $64.5M | 0.3% |
| 34 | ALMSAlumis Inc. | 2.0M | $56.6M | 0.3% |
| 35 | PRLDPrelude Therapeutics Inc. | 10.1M | $54.0M | 0.3% |
| 36 | RLAYRelay Therapeutics, Inc. | 2.8M | $52.9M | 0.3% |
| 37 | MIRMMirum Pharmaceuticals, Inc. | 445,975 | $52.2M | 0.3% |
| 38 | BCYCBicycle Therapeutics plc | 10.9M | $46.2M | 0.2% |
| 39 | ELVNEnliven Therapeutics, Inc. | 905,191 | $45.9M | 0.2% |
| 40 | CLDXCelldex Therapeutics, Inc. | 1.2M | $44.0M | 0.2% |
| 41 | VRDNViridian Therapeutics, Inc. | 2.4M | $43.8M | 0.2% |
| 42 | DSGNDesign Therapeutics, Inc. | 2.7M | $38.8M | 0.2% |
| 43 | TRDAEntrada Therapeutics, Inc. | 5.1M | $37.3M | 0.2% |
| 44 | FTHFaeth Therapeutics, Inc. | 1.3M | $32.2M | 0.2% |
| 45 | AKTSAktis Oncology, Inc. | 996,351 | $32.1M | 0.2% |
| 46 | NGNENeurogene Inc. | 991,691 | $31.2M | 0.2% |
| 47 | JBIOJade Biosciences, Inc. | 1.2M | $27.3M | 0.1% |
| 48 | TSHATaysha Gene Therapies, Inc. | 4.0M | $27.3M | 0.1% |
| 49 | RCUSArcus Biosciences, Inc. | 844,816 | $26.0M | 0.1% |
| 50 | IRONDisc Medicine, Inc. | 349,657 | $25.6M | 0.1% |
| 51 | ABSIAbsci Corporation | 2.1M | $24.7M | 0.1% |
| 52 | GENBGenerate Biomedicines, Inc. | 1.4M | $24.0M | 0.1% |
| 53 | DBVTDBV Technologies S.A. | 1.5M | $24.0M | 0.1% |
| 54 | XENEXenon Pharmaceuticals Inc. | 370,208 | $22.3M | 0.1% |
| 55 | TECXTectonic Therapeutic, Inc. | 607,788 | $20.9M | 0.1% |
| 56 | CERSCerus Corporation | 6.4M | $18.7M | 0.1% |
| 57 | CTMXCytomX Therapeutics, Inc. | 5.0M | $18.7M | 0.1% |
| 58 | DYNDyne Therapeutics, Inc. | 813,449 | $18.1M | 0.1% |
| 59 | CYTKCytokinetics, Incorporated | 211,267 | $18.0M | 0.1% |
| 60 | XNCRXencor, Inc. | 1.1M | $17.7M | 0.1% |
| 61 | SIONSionna Therapeutics, Inc. | 400,000 | $17.6M | 0.1% |
| 62 | NTLAIntellia Therapeutics, Inc. | 930,232 | $15.7M | 0.1% |
| 63 | PBLSParabilis Medicines, Inc. | 500,000 | $13.7M | 0.1% |
| 64 | MPLTMapLight Therapeutics, Inc. | 364,705 | $13.1M | 0.1% |
| 65 | AVLNAvalyn Pharma Inc. | 350,000 | $11.5M | 0.1% |
| 66 | EVMNEvommune, Inc. | 847,390 | $11.3M | 0.1% |
| 67 | BNTXBioNTech SE | 119,743 | $11.1M | 0.1% |
| 68 | TNGXTango Therapeutics, Inc. | 333,333 | $10.4M | 0.1% |
| 69 | AVTXAvalo Therapeutics, Inc. | 550,000 | $10.2M | 0.1% |
| 70 | SERASera Prognostics, Inc. | 5.5M | $10.0M | 0.1% |
| 71 | VSTMVerastem, Inc. | 2.5M | $9.5M | 0% |
| 72 | SGMTSagimet Biosciences Inc. | 952,996 | $7.4M | 0% |
| 73 | EIKNEikon Therapeutics, Inc. | 555,555 | $7.2M | 0% |
| 74 | LBRXLB Pharmaceuticals Inc. | 200,000 | $6.5M | 0% |
| 75 | VTVTvTv Therapeutics, Inc. | 148,314 | $5.6M | 0% |
| 76 | WVEWave Life Sciences Ltd. | 822,638 | $4.8M | 0% |
| 77 | TARAProtara Therapeutics, Inc. | 971,614 | $3.7M | 0% |
| 78 | TCRXTScan Therapeutics, Inc. | 2.8M | $2.7M | 0% |
| 79 | IMNMImmunome, Inc. | 55,306 | $1.2M | 0% |
| 80 | SKYESkye Bioscience, Inc. | 1.6M | $1.1M | 0% |
| 81 | SANASana Biotechnology, Inc. | 310,483 | $1.1M | 0% |
| 82 | ALGSAligos Therapeutics, Inc. | 83,055 | $479,227 | 0% |
| 83 | TYRATyra Biosciences, Inc. | 10,607 | $338,788 | 0% |
| 84 | Surrozen, Inc. Warrants @ $172.50 8/11/2026 (15 FOR 1) | 833,333 | $13,750 | 0% |
Source: SEC Form 13F-HR, reporting period 2026-06-30. Values are the manager's filed June-30-style quarter-end marks, not live prices. Research, not investment advice.